Asset
VK-2809
Viking Therapeutics Inc. Common Stock
Revenue
No revenue reported in loaded filings.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04173065 | phase2 | completed | 2019-11-15 | 2023-05-15 | Viking Therapeutics, Inc. | A Study to Assess the Efficacy and Safety of VK2809 for 52 Weeks in Subjects With Biopsy Proven NASH |
| NCT02927184 | phase2 | completed | 2016-09-28 | 2019-03-26 | Viking Therapeutics, Inc. | Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease |
FDA applications (0)
This company has no applications containing this asset.